Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs BigBearai Holdings Inc (BBAI) Price & Performance

AbbVie IncTrade
BigBearai Holdings IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs BigBearai Holdings Inc — how do they compare? AbbVie Inc trades at $248.89 (market cap $441.94B), while BigBearai Holdings Inc trades at $3.35 (market cap $1.60B). The key difference: AbbVie Inc is far larger — about 276.2× BigBearai Holdings Inc's market cap, and AbbVie Inc pays a 2.77% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.

ABBVBBAI
Market Cap
$441.94B$1.60B
Sector
HealthTechnology
52-Week High
$263.58$8.91
52-Week Low
$197.38$2.61
Enterprise Value
$506.19B$1.30B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

BigBearai Holdings Inc

BBAI trades at $3.27, up 8.64% with a bullish technical signal despite negative profitability metrics. The company reported Q2 2026 revenue growth of 13% and beat EPS estimates, though it remains unprofitable with a -65.2% net income margin. Recent news highlights defense contract execution and generative AI platform expansion for government clients.

The outlook remains challenging due to persistent losses and negative cash flow from operations, though analyst consensus leans neutral with 75% hold ratings. Key risks include execution on government contracts and achieving profitability, while technical indicators suggest near-term bullish momentum.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About BigBearai Holdings Inc

BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.

Read more on BBAI